Abstract
Overview
Introduction
Therapeutic vaccines have faced numerous setbacks in recent years. The only
three vaccines to reach the market have had insignificant sales, while the
pipeline has seen numerous high-profile failures and no new product launches
in three years. However, new 'off-the-shelf' generalized vaccines driven by
genomic advances promise to remedy the commercial drawbacks of early
personalized vaccines
Scope
- In-depth coverage of over 200 marketed and pipeline therapeutic vaccines,
including forecasts for sales up to 2010 and analysis of future trends
- Profiles of 16 leading therapeutic vaccines companies, their strategic
position, pipelines, partnerships and financial outlook
- Discussion of the many challenges facing therapeutic vaccine developers,
and how technology evolution is driving the industry forward
- Analysis of big pharma's level of interest in the sector, their
partnerships and pipelines
Report Highlights
Polyvalent, patient-specific vaccines have major commercial disadvantages that
have limited their uptake. However, rapid scientific progress means that
antigen-specific, generalized vaccines could soon offer comparable efficacy,
to complement their strong commercial profile. As a result generalized
vaccines are now starting to dominate the pipeline
Therapeutic vaccines development is seeing an increasing trend towards the use
of multiple antigens (and adjuvants), to attack cancers or HIV from multiple
angles. Combinations of therapies, and novel approaches such as prime-boost
regimens are expected to yield exciting results. Partnerships will therefore
become much more important
Therapeutic vaccine development is currently heavily weighted towards cancer
vaccines, which account for 60.6% of all pipeline projects. However, the
early-stage pipeline is starting to show greater interest in other therapeutic
areas, from HIV and infectious disease to nicotine addiction, CNS and
cardiovascular diseases
Reasons to Purchase
- Understand the scientific and commercial issues that are impeding
therapeutic vaccines, and learn how they can become a success in the future
- Assess the entire pipeline of therapeutic vaccines with an interactive
Excel model containing details of over 200 therapeutic vaccines in development
- Analyze and benchmark leading companies' strategies and pipelines, as well
as big pharma's interest in the sector
View Cart
